Harmony Biosciences Holdings Inc. (HRMY)
NASDAQ: HRMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 39.25 -0.23%
HRMY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.29B
- P/E (TTM)
- 12.69
- Forward P/E
- 5.62
- EPS (TTM)
- $3.10
- Dividend yield
- None
- 52-week range
- 25.52 – 43.49
- Day range
- 39.10 – 39.86
- Volume / Avg
- 547.00K / 893.02K
- Beta
- —
- Shares outstanding
- 58.24M
- Next earnings
- Nov 3, 2026
52-week range
HRMY stock today
Harmony Biosciences (HRMY) closed at $39.34 on Oct 7, down 0.05% (-$0.02), versus the S&P 500's 0.22% decline. At this level, HRMY sits in the middle of its 52-week range of $25.52 to $43.49: 9.5% below the high, set on Sep 3, 2026 and 54.2% above the low. HRMY is up 5.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 45.4%.
Harmony Biosciences trades at 12.7x its trailing twelve-month earnings per share of $3.10. Its forward P/E of 5.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Harmony Biosciences's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Harmony Biosciences
Company profileHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jeffrey M. Dayno M.D.
- Headquarters
- Plymouth Meeting, PA
- Employees
- 293
- IPO year
- 2020
- Website
- harmonybiosciences.com
Analyst forecast
ForecastConsensus (11 analysts)
buy
Avg. price target
$47.64+21.10%
- Strong buy 2
- Buy 5
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $1.03
HRMY news
All HRMY newsHarmony Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BHCBausch Health Companies Inc. | 6.15 | +2.16% | $2.30B | vs HRMY |
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs HRMY |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs HRMY |
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs HRMY |
| IRONDisc Medicine Inc. | 61.18 | -0.76% | $2.35B | vs HRMY |
| NRIXNurix Therapeutics Inc. | 22.73 | +0.58% | $2.36B | vs HRMY |
| PHVSPharvaris N.V. | 31.68 | +1.80% | $2.22B | vs HRMY |
| LQDALiquidia Corporation | 26.68 | +2.97% | $2.39B | vs HRMY |
Indexes, lists and sector
Harmony Biosciences stock FAQ
What is Harmony Biosciences's stock price today?
HRMY last traded at $39.34 as of Oct 7, 4:00 PM EDT, down 0.05% on the day. Prices are delayed at least 15 minutes.
When is Harmony Biosciences's next earnings date?
Harmony Biosciences is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $1.03.
What is HRMY's P/E ratio?
HRMY trades at a trailing P/E ratio of 12.69 and a forward P/E of 5.62.
Who is Harmony Biosciences's CEO?
Dr. Jeffrey M. Dayno M.D. is the chief executive officer of Harmony Biosciences Holdings Inc., which has about 293 employees.
What is the HRMY 52-week high?
The 52-week high for HRMY is $43.49 and the 52-week low is $25.52. The stock is currently 9.5% below its high.